Table 12.
Broadly utilized antigens and examples of corresponding cancer nanovaccines.
| Carrier | Antigen(s) | Adjuvant | Model | Ref. |
|---|---|---|---|---|
| PC7A nanoparticle | Melanoma: Trp1, Tnpo3 | Melanoma | [247] | |
| Polyplexes | Melanoma: Trp1 | CpG | Melanoma | [248] |
| Nanomicelle | Melanoma: Reps1 | Imidazoquinoline | Melanoma | [249] |
| Gold nanoparticle | Mucin glycopeptide | α-galactosyl ceramide | MUC1-tumor | [250] |
| Gold nanoparticle | mucin glycopeptide + ovalbumin |
Sigma Adjuvant System or TiterMax Gold |
Healthy animals |
[251] |
| Copolymer nanoparticle | Mucin 4β | Healthy animals |
[252] | |
| PLGA nanoparticle | NY-ESO-1 peptides | α-galactosyl ceramide | Healthy animals |
[253] |
| Vx3-alumina nanoparticle | Ubiquitinated proteins | STING agonist | Breast cancer | [254] |
| Silica nanoparticle | E7 GF001 peptide (HPV16) | HPV tumor | [255] | |
| Ultra-small nanoparticle | E7 long peptide (HPV16) | CpG | Head and neck cancer | [256] |